



Brumpton, B., Fritsche, L. G., Zheng, J., Davey Smith, G., & Åsvold, B. O. (2019). Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition. *Circulation: Genomic and Precision Medicine*, 12(1), 44-47. <https://doi.org/10.1161/CIRCGEN.118.002335>

Peer reviewed version

License (if available):  
Other

Link to published version (if available):  
[10.1161/CIRCGEN.118.002335](https://doi.org/10.1161/CIRCGEN.118.002335)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the American Heart Association at <https://doi.org/10.1161/CIRCGEN.118.002335> . Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/pure/user-guides/explore-bristol-research/ebr-terms/>

